Integra to Open New Braintree, Mass. Manufacturing Facility

Integra Lifesciences announced plans to restart manufacturing of its PriMatrix and SurgiMend tissue technologies in a new Braintree, Mass. facility.

The company has been reassessing its plans and timely to resume manufacturing these products since it received third-party audit findings for its Boston facility in March. The company no longer plans to restart manufacture of PriMatrix and SurgiMend at the Boston facility and will instead restart it at the Braintree site.

Integra said it will temporarily use the Boston site and equipment to support product and process development activities, in order to facilitate a smooth transition to the new site. The company aims to operationalize the Braintree facility in H1 2026.

“Given the advantages of the Braintree facility and the challenges of the Boston facility, the decision to consolidate our efforts at our new Braintree location enables us to focus our resources in one location. This represents a minimal difference in timing compared to restarting in our existing Boston facility, while limiting execution risk,” said Robert T. Davis, Jr., executive VP and president of Integra’s Tissue Technologies division.

PriMatrix is a dermal acellular repair scaffold derived from fetal bovine dermis for challenging wound management. It supports cellular repopulation and revascularization and is rich in Type III collagen, which is found in fetal dermis and active to develop and heal tissues.

SurgiMend is derived from fetal and neonatal bovine dermis as well. It is used for hernia repair as well as plastic and reconstructive surgery solutions.

“This new 100,000 square foot state-of-the-art facility provides us with the flexibility to implement more effective quality systems and efficient process flows, as well as significant capacity to support the future growth of PriMatrix and SurgiMend. The new facility is 10 miles from our current Boston location and central to where many of our Boston-area colleagues live, with ample space to house an attractive workplace,” Davis added. “We remain fully committed to bringing PriMatrix and SurgiMend back to the market and to achieving pre-market approval for SurgiMend PRS in implant-based breast reconstruction. We believe that focusing our efforts to operationalize the new Braintree facility is the right path to meet these commitments.”